Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TNYA |
---|---|---|
09:32 ET | 1547 | 3.8 |
09:36 ET | 280 | 3.765 |
09:41 ET | 200 | 3.8 |
09:45 ET | 8068 | 3.81 |
09:56 ET | 400 | 3.82 |
09:57 ET | 1000 | 3.8 |
10:01 ET | 100 | 3.8 |
10:06 ET | 200 | 3.8 |
10:08 ET | 100 | 3.8 |
10:15 ET | 800 | 3.78 |
10:19 ET | 100 | 3.77 |
10:28 ET | 100 | 3.785 |
10:35 ET | 300 | 3.76 |
10:37 ET | 800 | 3.76 |
11:02 ET | 300 | 3.75 |
11:04 ET | 3533 | 3.75 |
11:06 ET | 300 | 3.74 |
11:08 ET | 1400 | 3.75 |
11:09 ET | 1100 | 3.75 |
11:11 ET | 200 | 3.75 |
11:13 ET | 100 | 3.75 |
11:15 ET | 920 | 3.74 |
11:27 ET | 104 | 3.74 |
11:33 ET | 301 | 3.74 |
11:36 ET | 100 | 3.755 |
11:38 ET | 564 | 3.76 |
11:40 ET | 600 | 3.76 |
11:42 ET | 400 | 3.75 |
11:47 ET | 300 | 3.75 |
12:02 ET | 100 | 3.735 |
12:03 ET | 1200 | 3.74 |
12:05 ET | 3235 | 3.746 |
12:09 ET | 100 | 3.755 |
12:20 ET | 200 | 3.73 |
12:21 ET | 100 | 3.73 |
12:23 ET | 100 | 3.73 |
12:25 ET | 267 | 3.72 |
12:27 ET | 200 | 3.7 |
12:30 ET | 200 | 3.68 |
12:38 ET | 10664 | 3.75 |
12:39 ET | 1000 | 3.74 |
12:41 ET | 100 | 3.745 |
12:45 ET | 1040 | 3.75 |
12:48 ET | 200 | 3.77 |
12:52 ET | 300 | 3.765 |
12:54 ET | 100 | 3.765 |
12:56 ET | 100 | 3.765 |
12:57 ET | 200 | 3.765 |
12:59 ET | 100 | 3.765 |
01:01 ET | 100 | 3.765 |
01:03 ET | 4834 | 3.71 |
01:17 ET | 719 | 3.68 |
01:19 ET | 1000 | 3.7 |
01:21 ET | 404 | 3.7168 |
01:24 ET | 100 | 3.72 |
01:28 ET | 100 | 3.72 |
01:39 ET | 100 | 3.705 |
01:50 ET | 100 | 3.72 |
01:55 ET | 100 | 3.72 |
01:57 ET | 2695 | 3.68 |
02:00 ET | 100 | 3.68 |
02:02 ET | 300 | 3.68 |
02:08 ET | 100 | 3.69 |
02:11 ET | 200 | 3.68 |
02:13 ET | 1576 | 3.68 |
02:15 ET | 1412 | 3.68 |
02:18 ET | 2393 | 3.68 |
02:22 ET | 600 | 3.68 |
02:24 ET | 200 | 3.68 |
02:26 ET | 872 | 3.7 |
02:27 ET | 7100 | 3.7 |
02:29 ET | 100 | 3.71 |
02:31 ET | 100 | 3.71 |
02:33 ET | 200 | 3.73 |
02:36 ET | 5845 | 3.77 |
02:38 ET | 1774 | 3.789 |
02:40 ET | 500 | 3.82 |
02:42 ET | 200 | 3.82 |
02:44 ET | 300 | 3.82 |
02:45 ET | 17144 | 3.77 |
02:47 ET | 13994 | 3.79 |
02:49 ET | 200 | 3.8 |
02:51 ET | 9992 | 3.785 |
02:54 ET | 200 | 3.785 |
02:56 ET | 539 | 3.795 |
02:58 ET | 300 | 3.795 |
03:00 ET | 10011 | 3.795 |
03:02 ET | 889 | 3.79 |
03:03 ET | 600 | 3.8 |
03:05 ET | 400 | 3.805 |
03:09 ET | 100 | 3.805 |
03:12 ET | 400 | 3.805 |
03:14 ET | 28233 | 3.79 |
03:16 ET | 307 | 3.79 |
03:18 ET | 500 | 3.79 |
03:20 ET | 500 | 3.79 |
03:21 ET | 400 | 3.79 |
03:23 ET | 1000 | 3.795 |
03:25 ET | 16696 | 3.795 |
03:27 ET | 300 | 3.795 |
03:30 ET | 100 | 3.795 |
03:34 ET | 331 | 3.795 |
03:36 ET | 1600 | 3.77 |
03:38 ET | 100 | 3.77 |
03:39 ET | 200 | 3.77 |
03:41 ET | 5140 | 3.74 |
03:43 ET | 3061 | 3.725 |
03:45 ET | 800 | 3.73 |
03:48 ET | 339 | 3.74 |
03:50 ET | 509 | 3.75 |
03:52 ET | 1173 | 3.75 |
03:54 ET | 750 | 3.745 |
03:56 ET | 7299 | 3.745 |
03:57 ET | 5647 | 3.75 |
03:59 ET | 5844 | 3.74 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tenaya Therapeutics Inc | 289.7M | -2.3x | --- |
Solid Biosciences Inc | 288.2M | -2.2x | --- |
Inozyme Pharma Inc | 292.0M | -3.5x | --- |
Skye Bioscience Inc | 287.1M | -2.4x | --- |
Fractyl Health Inc | 267.3M | -3.4x | --- |
Anavex Life Sciences Corp | 313.2M | -7.5x | --- |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $299.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.65 |
Book Value | $2.04 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.